胃癌家族史患者接受幽門螺桿菌治療可降低患癌風險
作者:
小柯機器人發布時間:2020/2/10 9:10:45
韓國國立癌症中心Il Ju Choi研究小組近日取得一項新成果。經過不懈努力,他們對胃癌家族史患者接受幽門螺桿菌的治療的患癌風險進行了分析。這一研究成果於2020年1月30日發表在國際頂尖學術期刊《新英格蘭醫學雜誌》上。
幽門螺桿菌感染和胃癌家族史是胃癌的主要危險因素。根除幽門螺桿菌的治療是否能降低一級親屬中有胃癌家族史的人患胃癌的風險仍不清楚。
在這項單中心、雙盲、安慰劑對照的試驗中,研究組篩選了3100名胃癌患者的一級親屬。將其中1838名幽門螺桿菌感染者隨機分組,分別接受蘭索拉唑+阿莫西林+克拉黴素的根除治療或安慰劑治療。
共有1676名受試者被納入最終分析,其中治療組832名,安慰劑組844名。中位隨訪9.2年後,治療組中有10名受試者(1.2%)發生胃癌,安慰劑組中有23名(2.7%),風險比為0.45。10名胃癌患者中有5名患持續性幽門螺桿菌感染。根除了幽門螺桿菌感染的受試者中有0.8%的患者發生胃癌,而持續感染的受試者中胃癌發生率為2.9%,風險比為0.27。治療組中不良事件發生率為53.0%,顯著高於安慰劑組(19.1%),但均較輕微。
總之,對於有一級親屬胃癌家族史的幽門螺桿菌感染者,根除幽門螺桿菌治療可降低胃癌風險。
附:英文原文
Title: Family History of Gastric Cancer and Helicobacter pylori Treatment
Author: Il Ju Choi, M.D., Ph.D.,, Chan Gyoo Kim, M.D., Ph.D.,, Jong Yeul Lee, M.D.,, Young-Il Kim, M.D.,, Myeong-Cherl Kook, M.D., Ph.D.,, Boram Park, Ph.D.,, and Jungnam Joo, Ph.D.
Issue&Volume: 2020-01-29
Abstract:
Background
Helicobacter pylori infection and a family history of gastric cancer are the main risk factors for gastric cancer. Whether treatment to eradicate H. pylori can reduce the risk of gastric cancer in persons with a family history of gastric cancer in first-degree relatives is unknown.
Methods
In this single-center, double-blind, placebo-controlled trial, we screened 3100 first-degree relatives of patients with gastric cancer. We randomly assigned 1838 participants with H. pylori infection to receive either eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days) or placebo. The primary outcome was development of gastric cancer. A prespecified secondary outcome was development of gastric cancer according to H. pylori eradication status, assessed during the follow-up period.
Results
A total of 1676 participants were included in the modified intention-to-treat population for the analysis of the primary outcome (832 in the treatment group and 844 in the placebo group). During a median follow-up of 9.2 years, gastric cancer developed in 10 participants (1.2%) in the treatment group and in 23 (2.7%) in the placebo group (hazard ratio, 0.45; 95% confidence interval [CI], 0.21 to 0.94; P=0.03 by log-rank test). Among the 10 participants in the treatment group in whom gastric cancer developed, 5 (50.0%) had persistent H. pylori infection. Gastric cancer developed in 0.8% of participants (5 of 608) in whom H. pylori infection was eradicated and in 2.9% of participants (28 of 979) who had persistent infection (hazard ratio, 0.27; 95% CI, 0.10 to 0.70). Adverse events were mild and were more common in the treatment group than in the placebo group (53.0% vs. 19.1%; P<0.001).
Conclusions
Among persons with H. pylori infection who had a family history of gastric cancer in first-degree relatives, H. pylori eradication treatment reduced the risk of gastric cancer.
DOI: NJ202001303820507
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1909666